ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    FLOT7 | Germany
Previous Study | Return to List | Next Study

FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) (RAMSES/FLOT7)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02661971
Recruitment Status : Recruiting
First Posted : January 25, 2016
Last Update Posted : July 9, 2018
Sponsor:
Information provided by (Responsible Party):
IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest

Brief Summary:
Previous studies provide a strong theoretical rationale for the conduct of a randomized study evaluating the efficacy and safety of ramucirumab in combination with FLOT in the perioperative treatment of resectable adenocarcinoma of the stomach or GEJ.

Condition or disease Intervention/treatment Phase
Stomach Cancer Gastroesophageal Junction Cancer Drug: Docetaxel Drug: Oxaliplatin Drug: Calciumfolinat Drug: 5-Fluorouracil Biological: Ramucirumab Phase 2 Phase 3

Detailed Description:

This is a multicenter, randomized, controlled, open-label study including patients with locally advanced adenocarcinoma of the stomach and GEJ scheduled to receive perioperative chemotherapy.

The scope of the phase II portion of the trial is to evaluate pathological response rates of either regimen assessed by a centralized pathology and evaluate safety and tolerability.

Patients with locally advanced esophagogastric adenocarcinoma (i.e. cT2 any N or any T N-positive) with exclusion of distant metastases will be included in this trial.

Patients will be centrally reviewed and then stratified by tumor site (GEJ vs. gastric), histological type (intestinal vs. diffuse/mixed or unknown) and clinical stage (T1/2 vs. T3/4 and/or N+) and randomized 1:1 to receive either FLOT (Arm A) or FLOT/ramucirumab (Arm B).

Arm A (FLOT) Patients randomized to Arm A will receive 4 pre-operative cycles (8 weeks) of biweekly FLOT (Docetaxel 50 mg/m² in 250 ml NaCl 0.9%, iv over 1 h; Oxaliplatin 85 mg/m² in 500 ml G5%, iv over 2h; Leucovorin 200 mg/m² in 250 ml NaCl 0.9%, iv over 30 min; 5-FU 2600 mg/m², iv over 24 h, q2wk) of the preoperative treatment phase. Surgery in Arm A is planned to occur 4 to 6 weeks after d1 of last FLOT. Patients will receive 4 additional post-operative cycles (8 weeks) of FLOT in the post-operative treatment phase. Post-operative treatment should start 6 to 8 weeks, but at maximum 12 weeks after surgery.

Arm B (FLOT/ramucirumab) Patients randomized to Arm B will receive ramucirumab 8mg/kg i.v. over 60 min in combination with the FLOT regimen, which is administered identical to Arm A as described above. Surgery in Arm B is planned to occur 4 to 6 weeks after d1 of last FLOT/ramucirumab dose (but never earlier than 4 weeks after d1 of last FLOT/ramucirumab dose). Patients will receive 4 additional post-operative cycles (8 weeks) of FLOT/ramucirumab in the post-operative treatment phase followed by a total of 16 cycles of ramucirumab as a monotherapy (q2wk), starting 2 weeks after d1 of the last cycle of FLOT/ramucirumab.

In both of the arms, tumor assessments (CT or MRI) are performed before randomization and prior to surgery, and then every 3 months thereafter until progression/relapse, death or end of follow-up. A change from CT into MRI in the follow up period is possible at any time.

During treatment, clinical visits (blood cell counts, detection of toxicity) occur prior to every treatment dose. Safety of FLOT/ramucirumab will be monitored continuously by careful monitoring of all adverse events (AEs) and serious adverse events (SAEs) reported.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 908 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Perioperative RAMucirumab in Combination With FLOT Versus FLOT Alone for reSEctable eSophagogastric Adenocarcinoma - RAMSES - a Phase II/III Trial of the AIO
Study Start Date : June 2016
Estimated Primary Completion Date : April 2019
Estimated Study Completion Date : October 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Ramucirumab

Arm Intervention/treatment
Active Comparator: FLOT alone

Pre-operative therapy with FLOT followed by surgical resection followed by post-operative therapy with FLOT

  • Docetaxel 50 mg/m², d1
  • Oxaliplatin 85 mg/m², d1
  • Calciumfolinat 200 mg/m², d1
  • 5-Fluorouracil 2600 mg/m², d1
Drug: Docetaxel
Docetaxel 50 mg/m², d1
Other Name: TAXOTERE®

Drug: Oxaliplatin
Oxaliplatin 85 mg/m², d1
Other Name: ELOXATIN®

Drug: Calciumfolinat
Leucovorin 200 mg/m², d1
Other Name: Leucovorin

Drug: 5-Fluorouracil
5-FU 2600 mg/m², d1
Other Name: 5-FU

Experimental: FLOT + Ramucirumab

Pre-operative therapy with FLOT + ramucirumab followed by surgical resection followed by post-operative therapy with FLOT + ramucirumab

  • Ramucirumab 8mg/kg, d1
  • Docetaxel 50 mg/m², d1
  • Oxaliplatin 85 mg/m², d1
  • Calciumfolinat 200 mg/m², d1
  • 5-Fluorouracil 2600 mg/m², d1
Drug: Docetaxel
Docetaxel 50 mg/m², d1
Other Name: TAXOTERE®

Drug: Oxaliplatin
Oxaliplatin 85 mg/m², d1
Other Name: ELOXATIN®

Drug: Calciumfolinat
Leucovorin 200 mg/m², d1
Other Name: Leucovorin

Drug: 5-Fluorouracil
5-FU 2600 mg/m², d1
Other Name: 5-FU

Biological: Ramucirumab
Ramucirumab 8mg/kg, d1




Primary Outcome Measures :
  1. Phase II: Rate of pathological complete or subtotal responses (pCR/pSR): assessed according to Becker remission criteria [ Time Frame: 3 years ]
  2. Phase III: Overall Survival (OS): time from randomization to death of any cause [ Time Frame: 3 years ]
    Survival rates for the different time points will be determined using the Kaplan-Meier analysis of OS.


Secondary Outcome Measures :
  1. Phase II/III: R0 resection rate: reported descriptively [ Time Frame: 75 days ]
  2. Phase II/III: Progression Free Survival (PFS): time from randomization until disease progression, disease recurrence after surgery or death of any cause [ Time Frame: 3 years ]
    Survival rates for the different time points will be determined using the Kaplan-Meier analysis of PFS

  3. Phase II: Overall Survival (OS): time from randomization to death of any cause [ Time Frame: 3 years ]
  4. Phase III: Pathological response rates: assessed according to Becker remission criteria (Becker et al., 2003) [ Time Frame: 75 days ]
  5. Phase III: Progression Free Survival (PFS): time from randomization until disease progression, disease recurrence after surgery or death of any cause [ Time Frame: 3/5 years ]
  6. Phase III: Overall Survival (OS): time from randomization to death of any cause [ Time Frame: 3/5 years ]
  7. Phase II/III: Subgroup analyses: pCR/pSR according to subgroup (intestinal vs. diffuse/mixed or unknown and GEJ vs. gastric) [ Time Frame: 3/5 years ]
  8. Phase II/III: Subgroup analyses: OS (medians and rates) according to subgroup (intestinal vs. diffuse/mixed or unknown and GEJ vs. gastric) [ Time Frame: 3/5 years ]
  9. Phase II/III: Subgroup analyses: PFS (medians and rates) according to subgroup (intestinal vs. diffuse/mixed or unknown and GEJ vs. gastric) [ Time Frame: 3/5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed, resectable adenocarcinoma of the gastroesophageal junction (AEG/GEJ-type II-III) or the stomach (uT2, uT3, uT4, any N category, M0), or any T N+ M0 patient, with the following specifications:

    1. Medical and technical operability, according to the techniques described in Chapter 12 Surgical Therapy that are subtotal, total or transhiatal extended gastrectomy (patients planned to receive transthoracic esophagectomy are not eligible for the study)
    2. Participating sites in PETRARCA study: Negative HER-2 detection (score IHC HER-2 0 or IHC HER-2 1+ ); IHC HER-2 2+ and negative by FISH, SISH or CISH1
  2. No preceding cytotoxic or targeted therapy
  3. No prior partial or complete tumor resection
  4. Female and male patients ≥ 18 and ≤ 70 years. Patients in reproductive age must be willing to use adequate contraception during the study and for 7 months after the end of ramucirumab treatment (Appropriate contraception is defined as surgical sterilization (e.g., bilateral tubal ligation, vasectomy), hormonal contraception (implantable, patch, oral), and double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap)). Female patients with childbearing potential need to have a negative pregnancy test within 7 days before study start.
  5. ECOG ≤ 1
  6. Exclusion of distant metastasis by CT or MRI of abdomen, pelvis, and thorax, bone scan or MRI (if bone metastases are suspected due to clinical signs). Exclusion of the infiltration of any adjacent organs or structures by CT or MRI.
  7. Laparoscopic exclusion of peritoneal carcinomatosis, in case of ascites, peritoneal masses, or if otherwise suspected clinically
  8. Adequate hematological, hepatic and renal function parameters:

    1. Leukocytes ≥ 3000/mm³, platelets ≥ 100,000/mm³, neutrophil count (ANC) ≥1000/µL, hemoglobin ≥9 g/dL (5.58 mmol/L),
    2. Adequate coagulation function as defined by International Normalized Ratio (INR) ≤ 1.5, and a partial thromboplastin time (PTT) ≤ 5 seconds above the ULN (unless receiving anticoagulation therapy). Patients receiving warfarin/phenprocoumon must be switched to low molecular weight heparin and have achieved stable coagulation profile prior to randomization.
    3. Serum creatinine ≤ 1.5 x upper limit of normal
    4. Urinary protein ≤1+ on dipstick or routine urinalysis (UA; if urine dipstick or routine analysis is ≥2+, a 24-hour urine collection for protein must demonstrate <1000 mg of protein in 24 hours to allow participation in this protocol).
    5. Bilirubin ≤ 1.5 x upper limit of normal, AST and ALT ≤ 3.0 x upper limit of normal, alkaline phosphatase ≤ 6 x upper limit of normal
  9. Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures

Exclusion Criteria:

  1. Known hypersensitivity against ramucirumab, 5-FU, leucovorin, oxaliplatin, or docetaxel
  2. Other known contraindications against ramucirumab, 5-FU, leucovorin, oxaliplatin, or docetaxel
  3. Patients with esophageal cancer and those with adenocarcinoma of GEJ type I and all patients who are planned to have transthoracic esophagectomy.
  4. Clinically significant active coronary heart disease, cardiomyopathy or congestive heart failure, peripheral artery occlusive disease (PAOD, German pAVK), or any history of aortic aneurysm
  5. Any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina.
  6. Uncontrolled or poorly-controlled hypertension (>160 mmHg systolic or > 100 mmHg diastolic for >4 weeks) despite standard medical management.
  7. Clinically significant valvular defect
  8. Past or current history of other malignancies not curatively treated and without evidence of disease for more than 5 years, except for curatively treated basal cell carcinoma of the skin and in situ carcinoma of the cervix
  9. Criteria of unresectability, e.g.:

    • Radiologically documented evidence of major blood vessel invasion or encasement by cancer.
    • Patients with involved retroperitoneal (e.g. para-aortal, paracaval or interaortocaval lymph nodes) or mesenterial lymph nodes (distant metastases!)
  10. Known brain metastases
  11. Other severe internal disease or acute infection
  12. Peripheral polyneuropathy ≥ NCI Grade II
  13. Chronic inflammatory bowel disease
  14. Grade 3-4 GI bleeding within 3 months prior to enrollment.
  15. History of gastric perforation or fistulae in past 6 months
  16. Serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollment.
  17. The patient has undergone major surgery within 28 days prior to enrollment except staging laparoscopy.
  18. Receiving chronic antiplatelet therapy, including aspirin (Once-daily aspirin use (maximum dose 325 mg/day) is permitted), nonsteroidal anti-inflammatory drugs (including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar agents.
  19. History of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered "significant") during the 3 months prior to randomization.
  20. Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or ascites.
  21. On-treatment participation in another clinical study in the period 30 days prior to inclusion and during the study
  22. Subject pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment.
  23. Patients in a closed institution according to an authority or court decision (AMG § 40, Abs. 1 No. 4)
  24. Any other concurrent antineoplastic treatment including irradiation
  25. Current chronic alcohol, nicotine or drug abuse or history of chronic alcohol abuse during last 12 months. Nicotine abuse is defined as ≥ 25 pack-years (Willigendael et al., 2004).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02661971


Contacts
Contact: Salah-Eddin Al-Batran, Prof. Dr. +496976014420 albatran@ikf-khnw.de
Contact: Gerrit zur Hausen, Dr. +496976014518 zurhausen.gerrit@ikf-khnw.de

Locations
Germany
Institute for Clinical Cancer Research Krankenhaus Nordwest Recruiting
Frankfurt, Germany, 60488
Contact: Salah-Eddin Al-Batran, Prof    +496976014420      
Contact: Ulli S Bankstahl    +496976014596      
Sponsors and Collaborators
IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
Investigators
Principal Investigator: Salah-Eddin Al-Batran, Prof. Dr. Institute of Clinical Cancer Research (IKF), UCT - University Cancer Center, Frankfurt, Germany

Responsible Party: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
ClinicalTrials.gov Identifier: NCT02661971     History of Changes
Other Study ID Numbers: RAMSES/FLOT7
First Posted: January 25, 2016    Key Record Dates
Last Update Posted: July 9, 2018
Last Verified: July 2018

Additional relevant MeSH terms:
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Docetaxel
Oxaliplatin
Ramucirumab
Fluorouracil
Antibodies, Monoclonal
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs